surmount 4 tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial Patient Experience of Treatment with

Result in Fig

Risk factors such as high blood pressure, high cholesterol levels, obesity, and diabetes significantly contribute to the development and progression of CVD

Our guide on how to travel with tirzepatide covers airline rules, cold pack options, and temperature excursion risk management in detail

The obesity drug market is entering new phases, which includes Eli Lilly and Company advancing retatrutide, a next-generation triple-G therapy that could outperform its own marketed dual agonist Zepbound (tirzepatide)

Cure is a strong word, but the SYNERGY-NASH trial showed that 62% of participants on the highest dose achieved resolution of MASH after one year